Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Remo Panaccione

Showing results (1-10 of 467) with videos related to

Pageof 47
Sort By:
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|July 2, 2004
The ultimate therapeutic goal: establishing and maintaining quality of lifeRemo Panaccione
Inflammatory Bowel Diseases|August 6, 2008
Biological therapy in Crohn's disease: is it an issue of how hard you strike or how fast you strike?Remo Panaccione
Inflammatory Bowel Diseases|September 26, 2008
Are physicians biased in their choices of therapy to recommend to patients with IBD?Remo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 15, 2008
Crohn's disease: we are in it for the long haul. Interview by Paul C AdamsRemo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 3, 2005
Methotrexate" "lessons from rheumatology"Remo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|April 13, 2006
The approach to dysplasia surveillance in inflammatory bowel diseaseRemo Panaccione
Gastroenterology & Hepatology|April 11, 2014
Mechanisms of inflammatory bowel diseaseRemo Panaccione
Crohn'S & Colitis 360|February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference BiologicsRemo Panaccione
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's replyRemo Panaccione
Gastroenterology & Hepatology|April 7, 2025
Inflammatory Bowel Disease and Cardiovascular DiseaseRemo Panaccione
Pageof 47

Showing results (1-10 of 467) with videos related to

Sort By:
Pageof 47
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|July 2, 2004
The ultimate therapeutic goal: establishing and maintaining quality of lifeRemo Panaccione
Inflammatory Bowel Diseases|August 6, 2008
Biological therapy in Crohn's disease: is it an issue of how hard you strike or how fast you strike?Remo Panaccione
Inflammatory Bowel Diseases|September 26, 2008
Are physicians biased in their choices of therapy to recommend to patients with IBD?Remo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 15, 2008
Crohn's disease: we are in it for the long haul. Interview by Paul C AdamsRemo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 3, 2005
Methotrexate" "lessons from rheumatology"Remo Panaccione
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|April 13, 2006
The approach to dysplasia surveillance in inflammatory bowel diseaseRemo Panaccione
Gastroenterology & Hepatology|April 11, 2014
Mechanisms of inflammatory bowel diseaseRemo Panaccione
Crohn'S & Colitis 360|February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference BiologicsRemo Panaccione
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's replyRemo Panaccione
Gastroenterology & Hepatology|April 7, 2025
Inflammatory Bowel Disease and Cardiovascular DiseaseRemo Panaccione
Pageof 47